Biotechnology
Biotechnology prior art search
Search prior art for biotechnology inventions: sequences, vectors, assays, diagnostics, and recombinant methods.
Related biotechnology patents
- US11551786B2Board Of Regents, The University Of Texas SystemPublished 2023-01-10
A computer-implemented method of training a neural network to improve a characteristic of a protein comprises collecting a set of amino acid sequences from a database, compiling each amino acid sequence into a three-dimensional crystallographic structure of a folded protein, training a neural ...
- US10017769B2Institut PasteurPublished 2018-07-10
The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC ...
- JP7847619B2ザ・ブロード・インスティテュート・インコーポレイテッドPublished 2026-04-17
An engineered CRISPR-Cas9 chimeric RNA containing the following nucleotide sequence: NNNNNNNNNNNNNNNNNNNNNNNNGUUUUUAGAGCUAGAAAUAGCAAGUUAAAAAAAUAGGCUAGUCCGUUAUCA. An engineered CRISPR-Cas9 chimeric RNA containing the following nucleotide sequence: ...
- JP6329061B2ロシュ グリクアート アクチェンゲゼルシャフトPublished 2018-05-23
The present invention provides a method for generating a host cell that produces a recombinant antibody with enhanced Fc-mediated cellular cytotoxicity, comprising: providing a host cell that is capable of expressing a recombinant antibody comprising an IgG Fc region containing N-linked ...
- EP4289948B1The Regents of the University of CaliforniaPublished 2025-02-26
A single-molecule DNA-targeting RNA which binds to a site-directed modifying polypeptide and targets said site-directed modifying polypeptide to a specific location within a target DNA, wherein said single-molecule DNA-targeting RNA comprises: (a) a DNA-targeting segment comprising a nucleotide ...
- JP6723094B2ザ・ブロード・インスティテュート・インコーポレイテッドPublished 2020-07-15
An engineered, non-naturally occurring, clustered, equidistant, short-chain batch repeat (CRISPR)-CRISPR-related (Cas) (CRISPR-Cas) vector system, a) a first regulatory operably linked to one or more nucleotide sequences encoding one or more CRISPR-Cas system guide RNAs that hybridize to a target ...
- JP7426361B2ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニアPublished 2024-02-01
A pharmaceutical composition for treating a hematological malignancy in a human patient comprising a human T cell comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), the composition comprising: The CAR comprises a CD19 antigen-binding domain comprising the amino acid ...
- US10982208B2Gen9, Inc.Published 2021-04-20
Methods and devices are provided for preparing a protein array having a plurality of proteins. In one embodiment, the method includes providing a plurality of nucleic acids each having a predefined sequence and expressing in vitro a plurality of proteins from the plurality of nucleic acids. In ...
Search your own biotechnology idea
Describe your invention in plain language with its key technical features. Persoona queries Google Patents and ranks the closest results.
Why a prior art search matters for biotechnology
Biotech claims are dense and heavily litigated, so an early prior-art read protects years of research investment. It also surfaces the closest sequences and methods you will need to distinguish.
- Isolated natural products and correlations face eligibility limits after Myriad and Mayo; the inventive step usually has to be in a made or applied thing.
- Sequence listings and prior publications are frequently the closest art, not just patents.
- Enablement and written description are demanding for genus claims.